Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients

• Status: Active, not recruiting
• Trial end date: 2020-09-28
• Target enrollment: 0
• Participant gender: All

Summary

Prospective clinical trial to evaluate the efficacy of catheter lock with bicarbonate vs heparin in chronic hemodialysis patients. Two groups will be created, sodium bicarbonate lock group (experimental group) and heparin lock group (control group). Catheter pressures, flow, patency and infection outcomes will be compare between groups at different time points (30, 60 and 90 days).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital General "Dr. Miguel Silva" de Morelia; Hospital General “Dr. Miguel Silva” de Morelia
• Collaborators: NAUSLIFE HEMODIALYSIS CLINICS; Universidad Nacional Autonoma de Mexico
• Treatments: Calcium heparin; Heparin; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Patients who accept participation and sign informed consent.

• Incident or prevalent chronic hemodialysis patients who receive at least 2 sessions per week with 1 month of clinical stability defined as: no hospitalizations, no vascular access infections, no changes in blood flow prescription due to vascular access dysfunction.

• Patients with temporal catheter (Niagra 13.5 French/20 cm length, BARD Access System, Salt Lake City, Utah, USA) as vascular access for hemodialysis.

Exclusion Criteria:

• Catheter dysfunction at baseline

• On anticoagulation therapy

• Patients with known coagulopathy or hemophilia

• Patients with Child-Pugh B or C liver failure

• Patients with thrombocytopenia less than 100,000 u / L

• Patients with central vessel stenosis and vena cava syndrome, previously documented.

• Patients with vascular access exhaustion.

• Patients who have undergone more than 2 vascular approaches for hemodialysis catheters.

• Patients with heparin-induced thrombocytopenia